COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Multisystem Inflammatory Syndrome in Children (MIS-C)Coronavirus Disease 2019 (COVID-19)
- Interventions
- Other: SARS-CoV-2 and/or MIS-C Exposure
- Registration Number
- NCT04588363
- Brief Summary
The primary objectives of this study are:
* To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with SARS-CoV-2 and/or Multisystem Inflammatory Syndrome in Children (MIS-C), and
* To determine immunologic mechanisms and immune signatures associated with disease spectrum and subsequent clinical course during the year of follow-up.
- Detailed Description
This is a prospective, multicenter, observational cohort study to assess short and long-term clinical outcomes and immune responses after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and/or Multisystem Inflammatory Syndrome in Children (MIS-C) in children (e.g., defined as individuals who have not reached their 21st birthday at the time of enrollment). SARS-CoV-2 causes Coronavirus Disease 2019 (COVID-19)
Participants will be identified through active recruitment measures within hospitals and through ambulatory and laboratory-based databases of SARS-CoV-2 positive individuals \<21 years of age. The study will enroll a minimum of 250 subjects from a diverse racial/ethnic background, from participating medical centers in the United States. The study period of participation is 1 year (12 months).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 244
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detection from a respiratory specimen, and/or
- Meets criteria for Multisystem Inflammatory Syndrome in Children (MIS-C), and/or
- Meets criteria for MIS-C, except has involvement of only 1 organ system
Cases meeting clinical criteria for MIS-C but without known SARS-CoV-2 exposure, and who are being treated as MIS-C by the treating physician, but with negative SARS-CoV-2 PCR and pending or negative antibody testing, may be enrolled as subjects. If subsequent antibody testing is positive, cases will be labelled as confirmed MIS-C. If SARS-CoV-2 antibody testing is negative, subjects will be labeled at the end of the study as suspected/not confirmed MIS-C.
- Subject and/or parent/guardian who are not able to understand or be willing to provide informed consent and where applicable assent
--Note, for this observational cohort study, participation in other COVID-19 studies is not an automatic exclusionary criterion.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description SARS-CoV-2 positive children SARS-CoV-2 and/or MIS-C Exposure Individuals less than 21 years of age who fulfill one or more of the following criteria: * SARS-CoV-2 detection from a respiratory specimen, and/or * Meets criteria for MIS-C, and/or * Meets criteria for MIS-C, except has involvement of only 1 organ system
- Primary Outcome Measures
Name Time Method Proportion of Participants With Either COVID-19-Related Death, Rehospitalization, Major Complications after SARS-CoV-2 Illness and/or MIS-C at 6 Months Post Illness Presentation 6 Months Post Illness Presentation (Enrollment) Participants who experience Coronavirus Disease 2019 (COVID-19)-related death, rehospitalization or major complications after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) illness and/or multisystem inflammatory syndrome in children (MIS-C).
- Secondary Outcome Measures
Name Time Method Coagulation Abnormality by Fibrinogen Biomarker Up to 1 Year Post Illness Presentation (Enrollment) Characterization of dysregulation involving the coagulation system by fibrinogen laboratory test.
Cardiovascular System Dysregulation by Electrocardiogram (ECG) Up to 1 Year Post Illness Presentation (Enrollment) Characterization of cardiovascular system dysregulation(s) evaluated by standardized 12-lead electrocardiogram. ECG rhythms, intervals and voltages will be assessed. Cross reference: ECG and EKG are used interchangeably.
Hepatic/Metabolic Biomarker: Total Bilirubin Up to 1 Year Post Illness Presentation (Enrollment) Characterization of liver/metabolic function by serum total bilirubin laboratory test.
Other End Organ and/or functional abnormalities Occurring After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection/ Coronavirus Disease 2019 (COVID-19) and/or Multisystem Inflammatory Syndrome in Children (MIS-C) Up to 1 Year Post Illness Presentation (Enrollment) Identified by and characterized during standard of care assessments.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mortality 1 Year Post Illness Presentation (Enrollment) The occurrence of SARS-CoV-2 related death in participants.
Coagulation Abnormality by International Normalised Ratio (INR) Biomarker Up to 1 Year Post Illness Presentation (Enrollment) Characterization of dysregulation involving the coagulation system by INR laboratory test.
Coronary Artery Abnormalities Up to 1 Year Post Illness Presentation (Enrollment) Characterization of coronary artery abnormalities (e.g., by echocardiogram and, if performed for clinical indications, angiogram, as examples).
All-Cause Mortality 1 Year Post Illness Presentation (Enrollment) The occurrence of death in participants regardless of relationship to Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Hospitalization for Participants Enrolled as an Outpatient or Rehospitalization after First Admission in Hospitalized Participants Up to 1 Year Post Illness Presentation (Enrollment) Characterization of Participants who require:
* Hospitalization subsequent to enrollment as an outpatient for SARS-CoV-2/COVID-19 related illness and/or MIS-C, or
* Rehospitalization after discharge from their initial admission for SARS-CoV-2/COVID-19 related illness and/or MIS-C.
Abbreviations:
* Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
* Coronavirus Disease 2019 (COVID-19)
* Multisystem Inflammatory Syndrome in Children (MIS-C)Cardiovascular System Dysregulation by Troponin I Biomarker Up to 1 Year Post Illness Presentation (Enrollment) Characterization of cardiovascular system dysregulation by Troponin I laboratory test.
Pulmonary Abnormalities Up to 1 Year Post Illness Presentation (Enrollment) Pulmonary fibrosis (i.e., scarring) or other abnormalities detected by computerized tomography (CT) imaging.
Pulmonary Function Characteristics Up to 1 Year Post Illness Presentation (Enrollment) Characterization by pulmonary function tests (spirometry without bronchodilators).
Proportion of Participants with Coronavirus Disease 2019 (COVID-19)-Related Death after Multisystem Inflammatory Syndrome in Children (MIS-C) at 1 Year Post Illness Presentation 1 Year Post Illness Presentation (Enrollment) Participants who experience Coronavirus Disease 2019 (COVID-19)-related death, rehospitalization or major complications after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) illness and/or multisystem inflammatory syndrome in children (MIS-C).
Coagulation Abnormality by D-Dimer Biomarker Up to 1 Year Post Illness Presentation (Enrollment) Characterization of dysregulation involving the coagulation system by D-dimer laboratory test.
Coagulation Abnormality by Prothrombin Time (PT) and Activated Partial Thromboplastin Time (PTT) Biomarkers Up to 1 Year Post Illness Presentation (Enrollment) Characterization of dysregulation involving the coagulation system by PT and PTT laboratory tests.
Pulmonary Hypertension Up to 1 Year Post Illness Presentation (Enrollment) Prevalence of pulmonary hypertension by echocardiogram and standard of care assessments.
Cardiovascular System Dysregulation by B-type natriuretic peptide (BNP) Biomarker Up to 1 Year Post Illness Presentation (Enrollment) Characterization of cardiovascular system dysregulation by BNP laboratory test.
Cardiovascular System Dysregulation by Echocardiogram Up to 1 Year Post Illness Presentation (Enrollment) Characterization of cardiac function by echocardiogram (Echo), a test that uses high frequency sound waves (ultrasound) to make pictures of the heart. The test is also referred to as a diagnostic cardiac ultrasound.
Hepatic/Metabolic Biomarkers: Serum Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase ( ALT/SGPT)and Aspartate Aminotransferase (AST/SGOT) Up to 1 Year Post Illness Presentation (Enrollment) Characterization of liver/metabolic function by the following laboratory tests:
* alkaline phosphatase
* alanine aminotransferase (ALT/SGPT) and
* aspartate aminotransferase (AST/SGOT).Neurologic Abnormalities Up to 1 Year Post Illness Presentation (Enrollment) Characterization of neurologic sequelae of infection/disease.
Renal/Metabolic Biomarkers: Serum Creatinine and Blood Urea Nitrogen (BUN) Up to 1 Year Post Illness Presentation (Enrollment) Characterization of kidney/metabolic function by serum creatinine and blood urea nitrogen (BUN) laboratory tests
Renal/Metabolic Biomarker: Estimated glomerular filtration rate (eGFR) Up to 1 Year Post Illness Presentation (Enrollment) Characterization of kidney/metabolic function by the estimated glomerular filtration rate (eGFR) calculated value, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Health Related Quality of Life Up to 1 Year Post Illness Presentation (Enrollment) Assessment of health-related quality of life (HRQOL) after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection/ Coronavirus Disease 2019 (COVID-19) and/or multisystem inflammatory syndrome in children (MIS-C).
The Pediatric Quality of Life Inventory is a series of assessment instruments designed to measure the health-related quality of life of children. The PedsQL 4.0 provides an opportunity for the assessment of both overall (generic) quality of life as well as disease-specific quality of life.
The PedsQL 4.0 Generic Core Scales are appropriate for assessing health-related quality of life in both healthy and chronically ill children. The four scales making up this generic battery include Physical Functioning (8 items), Emotional Functioning (5 items), Social Functioning (5 items), and School Functioning (5 items).
Trial Locations
- Locations (20)
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
Children's Hospital Los Angeles
🇺🇸Los Angeles, California, United States
Children's Healthcare of Atlanta
🇺🇸Atlanta, Georgia, United States
Duke University Children's Health Center
🇺🇸Durham, North Carolina, United States
Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Monroe Carell Jr. Children's Hospital at Vanderbilt
🇺🇸Nashville, Tennessee, United States
Mount Sinai Kravis Children's Hospital
🇺🇸New York, New York, United States
Children's Hospital at Montefiore
🇺🇸Bronx, New York, United States
St. Louis Children's Hospital
🇺🇸Saint Louis, Missouri, United States
NewYork-Presbyterian Komansky Children's Hospital
🇺🇸New York, New York, United States
Mayo Clinic Rochester
🇺🇸Rochester, Minnesota, United States
Lucile Packard Children's Hospital Stanford
🇺🇸Palo Alto, California, United States
Cohen Children's Medical Center - Northwell Health
🇺🇸New Hyde Park, New York, United States
NewYork-Presbyterian Queens Hospital
🇺🇸Flushing, New York, United States
Loma Linda University Health
🇺🇸Loma Linda, California, United States
Hassenfeld Children's Hospital at NYU Langone
🇺🇸New York, New York, United States
Cincinnati Children's Hospital Medical Center
🇺🇸Cincinnati, Ohio, United States
NewYork-Presbyterian Brooklyn Methodist Hospital
🇺🇸Brooklyn, New York, United States
Medical University of South Carolina, Pediatric Rheumatology
🇺🇸Charleston, South Carolina, United States
UPMC Children's Hospital of Pittsburgh
🇺🇸Pittsburgh, Pennsylvania, United States